Latest Advancements on Gastro Floating Bi-Layer Tablets of Metformin and Pioglitazone for the Treatment of Diabetes Mellitus

The synergistic mode of action of pioglitazone hydrochloride (PG) and metformin hydrochloride (MH) has great potential for the treatment of type 2 diabetes mellitus. Because of their complementary modes of action, metformin hydrochloride (MH) and pioglitazone hydrochloride (PG) have great potential for the therapy of type 2 diabetes mellitus. Short half-life and the low absorption of metformin hydrochloride in lower gastrointestinal tract might restrict the action towards its expected therapeutic usefulness. This work aimed to create gastro-floating bilayer matrix tablets that would each contain two different drugs. The primary objective was to improve the absorption of pioglitazone hydrochloride through rapid release, while ensuring a sustained release of metformin hydrochloride. After optimisation, with a floating lag time of five minutes, the tablets floated in the testing medium for over twenty-four hours. They allowed the active substance to be released within 12 hours using a diffusion-dependent release mechanism with total release of the active substance being achieved within 5 minutes. Furthermore, it was viewed that, metformin hydrochloride yielded a stable plasma concentration, bio-availability increased by 1.5 times, Cmax decrease and Tmax was reduced. Furthermore, pioglitazone hydrochloride's in vivo behaviour matched that of the approved product. In addition to having improved mechanical and physical qualities, all formulations had a pleasing appearance. Stability testing and infrared spectroscopy analysis were done on the formulation, and the results showed that it produced the best results in terms of drug release and duration of buoyancy in vitro. The findings suggest that the medication and polymer did not interact chemically and that the formulation remained stable. The study finds that by achieving simultaneous sustained release of metformin hydrochloride with enhanced absorption and immediate release of pioglitazone hydrochloride, a gastro-floating bilayer tablet facilitated a more effective combination therapy for diabetes mellitus. The benefits of combining pioglitazone and metformin into a single tablet are reviewed in this review, with particular attention paid to how this combination may improve glycemic control, compliance, metabolic characteristics of people with type 2 diabetes mellitus.